PINP as an aid for monitoring patients treated with teriparatide.

Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH

Bone17 Dec 2010Cited by 69 (Europe PMC)

PMID21168536DOI10.1016/j.bone.2010.12.006PepBankPUB-21168536

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese patients, PINP increases above 10 μg/L at either 1 or 3 months occurred in 95% with teriparatide versus 3% with placebo.
In plain wordsIn Japanese patients, PINP increased above 10 μg/L at 1 or 3 months in 95% with teriparatide versus 3% with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP responder proportion at one or three months
Study
n = 207
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
PINP responders
95%
teriparatide
PINP responders
3%
placebo
Source sentences
Summary
The proportions of patients with an increase in PINP >10 μg/L at either 1 or 3 months were 3% in the placebo and 95% in the teriparatide group (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month, phase 3, multicenter trial of Japanese patients at high risk of fracture was conducted to assess the effects of teriparatide 20 μg/day on BMD, serum markers of bone turnover, and safety.
Summary · context
Two-hundred and seven subjects (93% female; median age 70 years) were randomized in double-blind fashion 2:1 to teriparatide versus placebo.
Report a problemFND-2116853605
02HumanRandomized controlled trialEfficacy outcome
In Japanese patients, lumbar spine BMD increases of at least 3% occurred in 94% with teriparatide versus 20% with placebo at 12 months.
In plain wordsIn Japanese patients, spine bone density rose at least 3% in 94% with teriparatide versus 20% with placebo at 12 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD responder proportion
Study
n = 207
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
Spine BMD responders
94%
teriparatide
Spine BMD responders
20%
placebo
Source sentences
Summary
The proportions of patients with a significant increase in lumbar spine BMD (increase from baseline ≥3%) at 12 months were 20% in the placebo and 94% in the teriparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month, phase 3, multicenter trial of Japanese patients at high risk of fracture was conducted to assess the effects of teriparatide 20 μg/day on BMD, serum markers of bone turnover, and safety.
Summary · context
Two-hundred and seven subjects (93% female; median age 70 years) were randomized in double-blind fashion 2:1 to teriparatide versus placebo.
Report a problemFND-2116853606
03HumanRandomized controlled trialEfficacy outcome
In Japanese patients, early PINP increases above 10 μg/L plus later spine BMD increases ≥3% occurred in 92% with teriparatide versus 0% with placebo.
In plain wordsIn Japanese patients, PINP increases at one or three months plus spine bone density increases at 12 months occurred in 92% versus 0% with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCombined PINP and BMD responder proportion
Study
n = 207
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
Combined responders
92%
teriparatide
Combined responders
0%
placebo
Source sentences
Summary
The proportions of patients with an increase in PINP >10 μg/L at 1 or 3 months and an increase in lumbar spine BMD ≥3% at 12 months was 0% of placebo group patients and 92% of teriparatide group patients (P<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month, phase 3, multicenter trial of Japanese patients at high risk of fracture was conducted to assess the effects of teriparatide 20 μg/day on BMD, serum markers of bone turnover, and safety.
Summary · context
Two-hundred and seven subjects (93% female; median age 70 years) were randomized in double-blind fashion 2:1 to teriparatide versus placebo.
Report a problemFND-2116853607
04HumanRandomized controlled trialEfficacy outcome
In Japanese patients at fracture risk, PINP increases above 10 μg/L occurred in 93% with teriparatide versus 3% with placebo at one month.
In plain wordsAt one month, PINP rose above 10 μg/L in 93% of Japanese teriparatide patients versus 3% with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP responder proportion at one month
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
PINP responders
93%
teriparatide at 1 month
PINP responders
3%
placebo at 1 month
Source sentences
Summary
The proportions of patients with an increase from baseline in PINP >10 μg/L at 1, 3, and 6 months were 3%, 0%, and 2% in the placebo, and 93%, 87%, and 83% in the teriparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month, phase 3, multicenter trial of Japanese patients at high risk of fracture was conducted to assess the effects of teriparatide 20 μg/day on BMD, serum markers of bone turnover, and safety.
Summary · context
Two-hundred and seven subjects (93% female; median age 70 years) were randomized in double-blind fashion 2:1 to teriparatide versus placebo.
Report a problemFND-2116853602
05HumanRandomized controlled trialEfficacy outcome
In Japanese patients at fracture risk, PINP increases above 10 μg/L occurred in 87% with teriparatide versus 0% with placebo at three months.
In plain wordsAt three months, PINP rose above 10 μg/L in 87% of Japanese teriparatide patients versus 0% with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP responder proportion at three months
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
PINP responders
87%
teriparatide at 3 months
PINP responders
0%
placebo at 3 months
Source sentences
Summary
The proportions of patients with an increase from baseline in PINP >10 μg/L at 1, 3, and 6 months were 3%, 0%, and 2% in the placebo, and 93%, 87%, and 83% in the teriparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month, phase 3, multicenter trial of Japanese patients at high risk of fracture was conducted to assess the effects of teriparatide 20 μg/day on BMD, serum markers of bone turnover, and safety.
Summary · context
Two-hundred and seven subjects (93% female; median age 70 years) were randomized in double-blind fashion 2:1 to teriparatide versus placebo.
Report a problemFND-2116853603
06HumanRandomized controlled trialEfficacy outcome
In Japanese patients at fracture risk, PINP increases above 10 μg/L occurred in 83% with teriparatide versus 2% with placebo at six months.
In plain wordsAt six months, PINP rose above 10 μg/L in 83% of Japanese teriparatide patients versus 2% with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePINP responder proportion at six months
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 12 monthsAs given in this study (human).
Measurements
PINP responders
83%
teriparatide at 6 months
PINP responders
2%
placebo at 6 months
Source sentences
Summary
The proportions of patients with an increase from baseline in PINP >10 μg/L at 1, 3, and 6 months were 3%, 0%, and 2% in the placebo, and 93%, 87%, and 83% in the teriparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month, phase 3, multicenter trial of Japanese patients at high risk of fracture was conducted to assess the effects of teriparatide 20 μg/day on BMD, serum markers of bone turnover, and safety.
Summary · context
Two-hundred and seven subjects (93% female; median age 70 years) were randomized in double-blind fashion 2:1 to teriparatide versus placebo.
Report a problemFND-2116853604

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In Japanese trial patients at high fracture risk, PINP increases at one month correlated best with lumbar spine BMD increases at 12 months.
In plain wordsIn Japanese trial patients at high fracture risk, early PINP increases were linked to later spine bone density increases.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEarly PINP association with later spine BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Correlation coefficient
0.76 r
PINP at 1 month and spine BMD at 12 months
Source sentences
Summary
Increases in PINP at 1 month correlated best with increases in lumbar spine BMD at 12 months (r=0.76; P<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month, phase 3, multicenter trial of Japanese patients at high risk of fracture was conducted to assess the effects of teriparatide 20 μg/day on BMD, serum markers of bone turnover, and safety.
Summary · context
Two-hundred and seven subjects (93% female; median age 70 years) were randomized in double-blind fashion 2:1 to teriparatide versus placebo.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2116853601

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.